Leveraged Buyouts
UPDATE: Elan Rejects Fresh Bid from Royalty
Elan rejects the newest bid from Royalty and seeks to look at other unsolicited interested parties.
AstraZeneca Acquires Pearl Therapeutics for US$1.15 Billion
AstraZeneca purchases Pearl Therapeutics for US$1.15 billion, making it the second firm in Britain to rebuild products through deal making.
UPDATE: Unless Severn Trent Engages in Discussion, Bid Consortium Will Walk Away
LongRiver Consortium will walk away from the proposed US$8.2 million bid unless Severn Trent engages in discussion with the company.
Marubeni Leaves Energy Arm In Gavilon’s Deal
Japan’s Marubeni said that it will leave Gavilon’s energy arm from the proposed takeover deal. (Photo : REUTERS)Logo of Marubeni Corp is seen at the company's head office in Tokyo Marubeni Corp, a Japanese trading house states that it will cut its planned takeover deal over Gavilon's energy business.